1. Manns M, et al. Lancet 2001; 358: 958                                                    
                                                                                        2. Fried M, et al. N Engl J Med 2002; 347: 975
3. Hadziyannis S, et al. Ann Intern Med 2004; 140: 346
                                                                                    4. Zeuzem S, et al. J Hepatol 2005; 43: 250
PEGASYS and COPEGUS: increasing SVR rates in all genotypes
2002
2004
2005
                511           453            436            134 
Fried2
Hadziyannis3
Zeuzem4
56%
63%
66%
54%
2001
Manns1
Peg-IFNa-2b (12KD) + RBV
PEGASYS + COPEGUS
48-week treatment duration
n=
0
10
20
30
40
50
60
70
100
90
80
Text Box: SVR (%)
SVR (%)